FCGR1A and cancer: CD64 expression probably therefore protects cancer cells from ADCC, and potentially complement-dependent cytotoxicity and antibody-dependent cell phagocytosis in vivo, explaining the disappointingly low efficacy of antibodies acting via these modes of action in the treatment of patients with AML.